FindTrial
Sign In

Study on clinical outcomes and predictions of ustekinumab treatment in patients with Crohn's disease

Study on clinical outcomes and predictions of ustekinumab treatment in patients with Crohn's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200067162
Enrollment
Unknown
Registered
2022-12-28
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Case series:No intervention

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1)Definite diagnosis of Crohn's disease 2)Receive ustekinumab for more than one time 3)Age=18 years old when receiving ustekinumab, inclusive 4)Following =6 months after treatment 5)Receive clinical and/or endoscopic evaluation for more than one time after treatment

Exclusion criteria

Exclusion criteria: 1)Receive ustekinumab for other diseases besides Crohn's disease 2)Incomplete clinical data

Design outcomes

Primary

MeasureTime frame
Disease progression;—

Secondary

MeasureTime frame
Effectiveness;Safety;Treatment consistence;—

Countries

China

Contacts

Public ContactQian Cao

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

caoq@zju.edu.cn13588706896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026